Alteration of corticothalamic perfusion ratios during a PTSD flashback

Depress Anxiety. 1996;4(3):146-50. doi: 10.1002/(SICI)1520-6394(1996)4:3<146::AID-DA9>3.0.CO;2-E.

Abstract

We performed a single photon emission computed tomography (SPECT) study of patients with posttraumatic stress disorder (PTSD) by measuring changes in regional cerebral blood flow (rCBF) during provocation by combat stimuli. A single patient experienced an actual flashback following exposure to combat sounds, exhibiting tearfulness, diaphoresis, tachypnea, and severe agitation. Results from his SPECT study demonstrated a dramatically altered ratio of cortical to subcortical perfusion during the flashback but not during the control scan. This altered pattern, which showed a peak of activity in the thalamus, was not consistent with global rCBF changes induced by hyperventilation. The perfusion pattern during the patient's control scan was qualitatively indistinguishable from any of the SPECT scans obtained for the other patients. This single case suggests a possible role for corticothalamic dysfunction in flashbacks.

Publication types

  • Case Reports
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Acoustic Stimulation
  • Arousal / physiology*
  • Brain Mapping
  • Cerebral Cortex / blood supply*
  • Cerebral Cortex / diagnostic imaging
  • Cerebral Cortex / physiopathology
  • Combat Disorders / diagnostic imaging*
  • Combat Disorders / physiopathology
  • Combat Disorders / psychology
  • Humans
  • Male
  • Mental Recall / physiology*
  • Middle Aged
  • Neural Pathways / blood supply
  • Neural Pathways / diagnostic imaging
  • Neural Pathways / physiopathology
  • Organotechnetium Compounds
  • Oximes
  • Regional Blood Flow / physiology
  • Technetium Tc 99m Exametazime
  • Thalamus / blood supply*
  • Thalamus / diagnostic imaging
  • Thalamus / physiopathology
  • Tomography, Emission-Computed, Single-Photon*
  • Veterans / psychology*

Substances

  • Organotechnetium Compounds
  • Oximes
  • Technetium Tc 99m Exametazime